These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 35682697)
1. Podocyte-Related Mechanisms Underlying Survival Benefit of Long-Term Angiotensin Receptor Blocker. Zhu X; Gao D; Albertazzi V; Zhong J; Ma LJ; Du L; Shyr Y; Kon V; Yang HC; Fogo AB Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682697 [TBL] [Abstract][Full Text] [Related]
2. Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis. Naito T; Ma LJ; Yang H; Zuo Y; Tang Y; Han JY; Kon V; Fogo AB Am J Physiol Renal Physiol; 2010 Mar; 298(3):F683-91. PubMed ID: 20042458 [TBL] [Abstract][Full Text] [Related]
3. Effects of combination PPARγ agonist and angiotensin receptor blocker on glomerulosclerosis. Matsushita K; Yang HC; Mysore MM; Zhong J; Shyr Y; Ma LJ; Fogo AB Lab Invest; 2016 Jun; 96(6):602-9. PubMed ID: 26999660 [TBL] [Abstract][Full Text] [Related]
4. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Chung EY; Ruospo M; Natale P; Bolignano D; Navaneethan SD; Palmer SC; Strippoli GF Cochrane Database Syst Rev; 2020 Oct; 10(10):CD007004. PubMed ID: 33107592 [TBL] [Abstract][Full Text] [Related]
10. Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels. Komine N; Khang S; Wead LM; Blantz RC; Gabbai FB Am J Kidney Dis; 2002 Jan; 39(1):159-64. PubMed ID: 11774115 [TBL] [Abstract][Full Text] [Related]
11. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection. Zoja C; Corna D; Gagliardini E; Conti S; Arnaboldi L; Benigni A; Remuzzi G Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1203-11. PubMed ID: 20719975 [TBL] [Abstract][Full Text] [Related]
12. Combined therapy of cilazapril and losartan has no additive effects in ameliorating adriamycin-induced glomerulopathy. Kim HJ; Ryu JH; Han SW; Park IK; Paik SS; Park MH; Paik DJ; Chung HS; Kim SW; Lee JU Nephron Physiol; 2004; 97(4):p58-65. PubMed ID: 15331931 [TBL] [Abstract][Full Text] [Related]
13. Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial. Esteghamati A; Noshad S; Jarrah S; Mousavizadeh M; Khoee SH; Nakhjavani M Nephrol Dial Transplant; 2013 Nov; 28(11):2823-33. PubMed ID: 24009294 [TBL] [Abstract][Full Text] [Related]
14. [Renoprotective effect of triple therapy with low-dose angiotensin receptor blocker, low-dose diuretic and Ca-antagonist in hypertensive type 2 diabetic patients with overt nephropathy]. Kuriyama S; Tomonari H; Ohtsuka Y; Ohkido I; Hosoya T Nihon Jinzo Gakkai Shi; 2003; 45(4):367-71. PubMed ID: 12806973 [TBL] [Abstract][Full Text] [Related]
15. Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway. Nijenhuis T; Sloan AJ; Hoenderop JG; Flesche J; van Goor H; Kistler AD; Bakker M; Bindels RJ; de Boer RA; Möller CC; Hamming I; Navis G; Wetzels JF; Berden JH; Reiser J; Faul C; van der Vlag J Am J Pathol; 2011 Oct; 179(4):1719-32. PubMed ID: 21839714 [TBL] [Abstract][Full Text] [Related]
16. Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin. Lebel M; Rodrigue ME; Agharazii M; Larivière R Am J Hypertens; 2006 Dec; 19(12):1286-92. PubMed ID: 17161776 [TBL] [Abstract][Full Text] [Related]
18. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019 [TBL] [Abstract][Full Text] [Related]
19. Regression of existing glomerulosclerosis by inhibition of aldosterone. Aldigier JC; Kanjanbuch T; Ma LJ; Brown NJ; Fogo AB J Am Soc Nephrol; 2005 Nov; 16(11):3306-14. PubMed ID: 16192423 [TBL] [Abstract][Full Text] [Related]
20. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Shibata S; Nagase M; Yoshida S; Kawachi H; Fujita T Hypertension; 2007 Feb; 49(2):355-64. PubMed ID: 17200434 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]